Results 191 to 200 of about 354,007 (274)

Case Report: Histamine-mediated inflammation and mast cell modulation in central serous chorioretinopathy: a two case illustrations. [PDF]

Front Immunol
KamaliZonouzi S, Babaei Zadeh P, Popovic MM, Gorin MB, Eshkoly-Lior T.   +4 more
europepmc   +1 more source

Identification of gemilukast as a bifunctional molecule with lipid-lowering and anti-inflammatory activities. [PDF]

Front Immunol
Liu Y, Wang Y, Wang R, Yang Q, Pan G, Zhang R.   +5 more
europepmc   +1 more source

Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report. [PDF]

ESMO Open
Smarsly D, Kreuzberg N, Langhorst C, Scheffler M, Siebolts U, Lennartz S, Koll P, Glaser AC, Franklin C.   +8 more
europepmc   +1 more source

Treatable traits of small airway dysfunction in children with asthma and advances in small airway-targeted therapeutic research: a narrative review. [PDF]

Transl Pediatr
Qin T, Han W, Yu Y, Yang J.
europepmc   +1 more source

The Pivotal Role of Plant Derivatives and Eicosanoid Signaling Modulation in Counteracting Cardiomiopathy. [PDF]

Int J Mol Sci
Ussia S, Ritorto G, Macrì R, Serra M, Tavernese A, Altomare C, Dardano DM, Idone C, Palma E, Muscoli C, Volterrani M, Barillà F, Mollace V, Mollace R.   +13 more
europepmc   +1 more source

The PGD₂/DP2 axis promotes pro-inflammatory responses but attenuates an antigen-presenting role of human basophils. [PDF]

Commun Biol
Luo J, Chen W, Lett MJ, Yu S, Luo W, Coakley E, Kazani S, Shikatani EA, Hinks TSC, Sandham DA, Pavord ID, Klenerman P, Xue L.   +12 more
europepmc   +1 more source

A Narrative Review of Recent Developments in Aspirin Therapy After Desensitization in NSAIDs-Exacerbated Respiratory Disease. [PDF]

J Inflamm Res
Patel PK, Sharma Khatiwada A, Andrews PJ, Scadding GK, Pendolino AL.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Leukotriene-receptor antagonists

Lancet, The, 1999
Leukotriene-receptor antagonists are the first novel class of antiasthma drugs to become available over the past three decades. They have an unique profile in that they are a hybrid of an anti-inflammatory and bronchodilator drug, and they can be taken as a tablet once or twice daily.
Brian Lipworth
exaly   +5 more sources